Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02277613 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
A Phase 2 study, sponsored by Healios K.K..
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02277613: Clinical Trial Phase 2 study, sponsored by Healios K.K..
NCT02277613 is a Phase 2 study that was terminated before completion, run by Healios K.K.. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02277613, a Phase 2 study, was terminated before completion, sponsored by Healios K.K..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
Primary Outcome
To compare the difference in the incidence and severity of adverse events between AMI MultiStem therapy treated subjects and Sham treated subjects
Interventions
- OTHER Sham
- BIOLOGICAL AMI MultiStem cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-01 |
| Phase | Phase 2 |
Why NCT02277613 stopped before completion
NCT02277613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT02277613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02277613 about?
NCT02277613 is a clinical study titled "A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction". This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
What is the current status of trial NCT02277613?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-12. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02277613?
The interventions under investigation include: Sham (OTHER), AMI MultiStem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02277613?
This trial is sponsored by Healios K.K., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02277613's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia